author-photo

J. Hicks

Beatson West of Scotland Cancer Centre

27

Papers

99

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience

2020 Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions

2019 Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Hypofractionated radiotherapy with chemotherapy for stage 3 non-small cell lung cancer: a single centre experience

2019 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Can patient selection for stereotactic ablative radiotherapy (SABR) in patients with early stage lung cancer patients be improved by a central multidisciplinary team

2018 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
P1.16-26 Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) with 50 Gray in 5 Fractions (50Gy/5f)

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET)

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (41)
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P2.05-049 Radical Treated NSCLC Radiotherapy Patients: A Prospective Study of Toxicities and Outcomes: Topic: Toxicities

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P1.05-035 SABR for Medically Inoperable Early Stage NSCLC at the Beatson West of Scotland Cancer Centre: Outcomes and Toxicity: Topic: SBRT

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Poster SessionP3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)